Moolec Science SA · NASDAQ:MLEC
Moolec Science SA — SPAC Merger (June 2022)
42 slides from Moolec Science SA's SPAC merger presentation, Jun 14, 2022
Slide 1: Investor Presentation
Investor Presentation June 2022
Slide 2: Disclaimer
Disclaimer This presentation was prepared for informational purposes only by Moolec Science Limited, (“Moolec”) and LightJump Acquisition Corporation (“LightJump”) and is intended to be provided only to accredited institutional investors who are considering an investment in Moolec. The information p
Slide 3: Presenters
Presenters LightJump Union Acquisition Group Bioceres Group Moolec Science Moolec Science Moolec Science Robert Bennett Kyle P. Bransfield Federico Trucco Gastón Paladini José López Lecube Amit Dhingra Chairman & CEO CEO & Co-Founder CEO CEO & Co-Founder CFO CSO 25+ years equity sponsor in CEO & Dire
Slide 4: Overview of SPAC Business Combination, Capital Structure, and Use of Proceeds
Overview of SPAC Business Combination, Capital Structure, and Use of Proceeds Moolec & LJ Capital Structure Motivations for Business Combination being listed • Lightjump Acquisition Corp. (NASDAQ: LJAQ) is a $138M • As a result of the transaction, the Combined Company • Become a Category Leader by b
Slide 5: Transaction Overview – Capitalization, Sources, and Uses
Transaction Overview – Capitalization, Sources, and Uses Transaction Sources and Uses Redemptions Scenarios Pro–Forma Valuation Redemptions Scenarios 0% 50% 100% Sources 0% 50% 100% Pro Forma Shares Outstanding 1, 3 M shares 50.4 43.5 37.69 LJAQ cash in trust 1 $138 M $69 M $0 M Illustrative Share P
Slide 6: Investment Highlights
Investment Highlights 01 Pioneer of the 4th technological pillar within the alternative protein industry as a category creator 02 Focused on highest impact segment (ingredients) of the marketplace 03 Unmatched value proposition with cost, scale, nutrition and organoleptic advantages 04 Long-standing
Slide 7: Planting the Future of Food
Planting the Future of Food Moolec is a science-based food ingredient company using Molecular Farming technology. Our purpose is to upgrade taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. 07 SCIENCE IN ALTERNATIVE PROTE
Slide 8: Moolec by the Numbers
Moolec by the Numbers Moolec is pioneering the future of alternative protein ingredient production $72B 1st 15+ Total Addressable Markets To achieve a bovine protein Global Patents & (2025E)1 with plants for food Patent Applications 60X 35X 100% Less GHG Emissions Less Land Usage Animal-Free vs. Cat
Slide 9: The Industry
The Industry
Slide 10: Present Context: Ring of Fire
Present Context: Ring of Fire COVID-19 has amplified the weakness of the global food supply chain and the dismal outlook on food security Economic1 Enviromental3 Human Health5 Pests & Diseases6 • War in Ukraine is • Rising average global • Long-term consumption of • The $100B toll of a pig amplifying
Slide 11: The world needs more and sustainable food
The world needs more and sustainable food Population growth could reach 10 billion people by the year 2050 Crop production would need to double to support the demand Inefficient conversion1 Unsustainable system2 Consumer’s Shift3 40% 15% 25% + = 25 kg 15.400 lts 1 kg Croplands GHG Vegetarian, vegan
Slide 12: Alternative Proteins Industry emerged to address the problems
Alternative Proteins Industry emerged to address the problems Companies use different technologies and ingredients based on plants, cells, and microbes Plant-Based1 Fermentation2 Cultured Meat3 Products made from plants that are Use of intact live microorganisms to Genuine animal meat produced by al
Slide 13: Total Addressable Market
Total Addressable Market Alternative protein consumption projections (retail prices)1 ~$300B 300 CAGR ~17% 200 ~$140B 100 ~$65B ~$40B 0 2022 2025 2030 2035 13 1 Moolec's internal analysis based on publicly disclosed information for the industry, primarily the GFI State of Industry Report 2021 (March
Slide 14: The challenge: Reach parity with animal-based food
The challenge: Reach parity with animal-based food Taste and Nutritional Scalability texture values and low costs 14 SCIENCE IN ALTERNATIVE PROTEINS
Slide 15: The solution: Moolec as Category Creator
The solution: Moolec as Category Creator 1 Plant-based Fermentation Cultured meat Molecular Farming Taste and texture Nutritional values Scalability and low costs Plants Science Plants + Science 15 1 Moolec's internal analysis based on publicly disclosed information for the industry and management e
Slide 16: The Technology
The Technology
Slide 17: Moolec's Technology
We introduce the real DNA of proteins' genes to the seeds of the main plants used in food to give back real taste and nutrition to products using Molecular Farming technologies Moolec’s Technology 17 SCIENCE IN ALTERNATIVE PROTEINS
Slide 18: Molecular Farming: A cost-effective way to produce Alternative Proteins
Molecular Farming: A cost-effective way to produce Alternative Proteins1 , 18 1 Based on Moolec's internal analysis based on publicly disclosed information for the industry and management estimates SCIENCE IN ALTERNATIVE PROTEINS
Slide 19: Molecular Farming vs. Animal-based production system
Molecular Farming vs. Animal-based production system 8X less 1 2 3 19 1 https://ourworldindata.org/agricultural-land-by-global-diets 2 https://waterfootprint.org/en/water-footprint/product-water-footprint/water-footprint-crop-and-animal-products/ SCIENCE IN 3 https://ourworldindata.org/food-choice-v
Slide 20: Molecular Farming Landscape
Molecular Farming Landscape 1 The industry is growing with stronger recognition of the advantages of Molecular Farming Moolec has a competitive edge in using both soybean and pea seeds Nobell Foods2 Miruku3 Mozza4 Kyomei5 Dairy proteins in Soybeans Dairy proteins in Soybean Dairy Dairy proteins prot
Slide 21: The Company
The Company
Slide 22: Moolec, a spin off from Bioceres Group
Moolec, a spin off from Bioceres Group 1 Science for a Science applied to sustainable alternative agriculture proteins + + (Bioceres S.A. - Private entity) 22 1 Bioceres Group is a private entity SCIENCE IN ALTERNATIVE PROTEINS
Slide 23: Moolec's Pathway to Public Listing
Moolec’s Pathway to Public Listing 10 years building our technology Technology scale-up Lab Pilot Patents Industrial scale Spin off From Safflower Company Expected plant Approvals Commercialization (UK Entity) to Soy Building Listing 2008 2014 2018 2020 2021 2022 IP Incorporation (Bioceres S.A. - Pr
Slide 24: World Class Team
World Class Team Gastón Paladini, MBA Henk Hoogenkamp, Ph.D Amit Dhingra, Ph.D José López Lecube, MBA CEO & Co-Founder CPO & Co-Founder CSO CFO 10 years in the traditional food 10+ years in food and bio-materials 20+ years in genomics and plant 15 years in strategic roles for multinational industry
Slide 25: Board of Directors
Board of Directors FedericoTrucco, Ph.D Juan Sartori, B.S. Oscar León Betancor, CPA Gastón Paladini, MBA Bioceres' CEO since 2011. Biochemist with International entrepreneur, investor, For the last 10 years, he has been a Solid background in Financial a Ph.D degree in Crop Sciences from the Uruguaya
Slide 26: Go-To-Market
Go-To-Market
Slide 27: Business Model
Business Model From farm to fork: Moolec's innovation and traceability starts at the beginning of the food ingredients value chain Unique Animal-free B2B MODEL Food Producers & CPG Contracted ingredients Companies Modified Growers & Retail / Food Consumers Seeds Downstream Services Moolec’s IP Ingred
Slide 28: POORK+
Enhanced plant-based ingredients with real animal proteins inside1 POORK+ SOY+PORK A N I M A L F R E E Safflower Soy Pea Dairy Ingredients Nutritionals Oils Meat Replacements Meat Replacements Plant-based chymosin, a Plant-based GLA oil Plant-based real porcine proteins Plant-based real bovine prote
Slide 29: Pipeline Status
Pipeline Status R&D Prototype Scale-up Production Commercialization SAM 2025 Dairy RY AP TO Ingredients PR GULA ~$350M1 OVALS RE Meat Proteins Chymosin SPC Dairy Nutritional TO RY AP Ingredients Oils PR ~$1.5B2 GULA OVALS RE Bovineacid Gamma linolenic Protein Chymosin GLA SPC SONOVA® Meat Replacemen
Slide 30: Regulatory Pathway
Regulatory Pathway Cultivation Food 1. Cultivation approvals are not needed 1. Approvals: for food and feed (products world-wide and by-products) 2.Moolec cultivates in the USA and 2.Codex Alimentarius Guidelines for Food Argentina Safety: • USA: Moolec's plants may not be subject • USA: US-FDA | GR
Slide 31: Patent Portfolio: IP Driven
Patent Portfolio: IP Driven Moolec holds as owner and licensee an international patent portfolio for its Molecular Farming products andstands on a growing IP strategy with great understanding of the plant-biotech landscape offering a competitive advantage on its execution Current Potential IP Opport
Slide 32: Today most consumers accept GMO Food
Today most consumers accept GMO Food 98% of all soybeans grown in the USA are GMO, and Impossible Burger's successful rollout confirmed that GMO is no longer a material issue in the US consumer's minds1,2 Transparency and the cause's purpose are key Discussion gravitates around science, hunger and cl
Slide 33: Moolec addresses directly 10 of the 17 SDGs
Moolec addresses directly 10 of the 17 SDGs We use SDGs and the 2030 Agenda as guidelines to strategically align our business in search of building a more equitable, resilent, and sustainable food system1,2 From ending poverty, hunger to responding to climate change, food and agriculture lie at the
Slide 34: Status & Next Steps
Status & Next Steps
Slide 35: LTM Key Milestones
LTM Key Milestones 1. Soybean 2. GLA / Safflower 3. FDA / Regulatory 4. Back Crossing Safflower Greenhouse & T1 Seed Stage Scaling up seed multiplication Chymosin GRAS Chymosin x GLA Pre-submission Stage BC1 Stage 1 5. Partnership with 6. Contracts, MOUs and MTAs Global conglomerate with strong pres
Slide 36: Moolec's Future Plans
Moolec's Future Plans 2023 2024 Partnership with food Seed Product Pre-industrial producers and multiplication + definition & scaling-up + New ingredients companies Field trials prototyping Regulatory approvals 36 SCIENCE IN ALTERNATIVE PROTEINS
Slide 37: Let's empower science in food for the good of the planet
Let’s empower science in food for the good of the planet hello@moolecscience.com Follow us! www.moolecscience.com
Slide 38: Addendum
Addendum
Slide 39: LightJump
LightJump Deal Team Robert Bennett Chairman & CEO • 25+ years equity sponsor in technology, advanced manufacturing, and digital media • Co-Founder and CEO of View Market (sold to Gow Media) • Co-Founder of multiple IT services companies Investment Team • Co-Founder of what became Match.com, sold to
Slide 40: LightJump
LightJump Digital Transformation Blockchain Mobility Category Cybersecurity Bank disintermediation Space Creators DTC Industrial Fundamental Atributes • Large Markets • Category Leaders • Defensible Moats • Growth Inflections Points 40 SCIENCE IN ALTERNATIVE PROTEINS
Slide 41: Union Acquisition Group
Union Acquisition Group IPO of Union Acquisition Corp I & II, Focused on a business Proven track record of identifying, Leading Serial Sponsor with 2 of the NYSE & NASDAQ listed SPACs combination with an innovative, acquiring, and promoting growing most successful De-SPAC transactions sponsored by J
Slide 42: Bioceres Group
Bioceres Group Vision Business Divisions Bioceres is Latin America’s Functional flagship group in the ag-biotech Foods space, advancing the life sciences ecosystem by investing in high impact technologies and science based companies Biomaterials Bioceres Bioceres Bioceres Tech Services Crop Solutions